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Electroacupuncture (EA) possesses various therapeutic eﬀects, including alleviation of pain, reduction of inﬂammation and
improvement of sleep disturbance. The mechanisms of EA on sleep improvement, however, remain to be determined. It has
been stated in ancient Chinese literature that the Anmian (EX17) acupoint is one of the trigger points that alleviates insomnia.
We previously demonstrated that EA stimulation of Anmian acupoints in rats during the dark period enhances non-rapid
eye movement (NREM) sleep, which involves the induction of cholinergic activity in the nucleus tractus solitarius (NTS). In
addition to cholinergic activation of the NTS, activation of the endogenous opioidergic system may also be a mechanism by
which acupuncture aﬀects sleep. Therefore, this study was designed to investigate the involvement of the NTS opioidergic system
in EA-induced alterations in sleep. Our present results indicate that EA of Anmian acupoints increased NREM sleep, but not
rapid eye movement sleep, during the dark period in rats. This enhancement in NREM sleep was dose-dependently blocked
by microinjection of opioid receptor antagonist, naloxone, and the μ-opioid receptor antagonist, naloxonazine, into the NTS;
administrations of δ-receptor antagonist, natrindole, and the κ-receptor antagonist, nor-binaltrophimine, however, did not aﬀect
EA-induced alterations in sleep. Furthermore, β-endorphin was signiﬁcantly increased in both the brainstem and hippocampus
after the EA stimuli, an eﬀect blocked by administration of the muscarinic antagonist scopolamine into the NTS. Our ﬁndings
suggestthatmechanismsofEA-inducedNREMsleepenhancementmaybemediated,inpart,bycholinergicactivation,stimulation
of the opiodergic neurons to increase the concentrations of β-endorphin and the involvement of the μ-opioid receptors.
1.Introduction
Electroacupuncture (EA), which consists of passing a con-
tinuous electric current through needles inserted into the
acupoints to obtain the therapeutic eﬀects, that is, allevia-
tion of pain, reduction of inﬂammation and management
of insomnia, is modiﬁed from the traditional Chinese
acupuncture. Insomnia is one of the most common sleep
disorders and it has been demonstrated that the eﬀectiveness
rate of acupuncture for relieving insomnia is about 90%
[1, 2]. Several speciﬁc acupoints have been identiﬁed for
insomnia treatment based upon the diﬀerentiation and signs
of symptoms according to traditional Chinese medicine.
Among the acupoints used, Shenmen (HT7), Sanyinjiao
(SP6) and Anmian (EX17) are the most common, although
other acupoints may also be used, such as Neiguan (PC6),
Zusanli (ST36), Taichong (LR3), Baihui (DU20), Dazhui
(DU40), Tainzhu (BL10), Bishu (BL20) and Zhongwan
(RN12) [3, 4].
The mechanisms by which EA functions to alleviate
clinical symptoms remain largely unknown, although appli-
cationsofEAhavebeenwidelydescribedintheChineseliter-
ature.Thespinalgate-controltheory[5]andtheactivationof
centralendorphinand/ormonoaminergicsystems(i.e.,sero-
tonin and norepinephrine) [6] have been hypothesized in
mediating the EA-induced analgesia. In addition, acupunc-
turemayreducetheinﬂammation-inducedelevationofbody
temperature by suppressing hypothalamic production of
pro-inﬂammatory cytokines [7]. The central opioidergic and
serotonergic systems also mediate the suppressive eﬀects of
acupunctureoncapsaicin-inducedneurogenicinﬂammation
[8].Recentﬁndingssuggestthattheinductionofvagusnerve2 Evidence-Based Complementary and Alternative Medicine
activityappearstobeanothersigniﬁcantfactorformediating
the action of acupuncture [9, 10]. The caudal nucleus tractus
solitarius (NTS) may be activated by acupuncture, since
NTS is located in the dorsomedial medulla oblongata and
receives aﬀerents primarily from the vagus and glossopha-
ryngeal nerves [11]. Ascending projections from the NTS
are traced through the lateral and dorsal tegmentum and
periventriculargrayuptotherostralponsandmidbrain,and
terminate in the parabrachial nucleus, which in turn projects
to the thalamus, hypothalamus, preoptic area, bed nucleus of
the stria terminalis, amygdala and the frontal cortex, regions
commonly belonging to the visceral-limbic forebrain [12,
13]. From these anatomical data, it does not appear that the
predominant eﬀect of the NTS is via the reticular activating
system but instead is via limbic forebrain structures, which
are implicated in the sleep regulation. Furthermore, the low-
frequency electrical stimulation of the medullary reticular
formation,particularlythedorsalreticularformationandthe
caudal NTS, produces cortical synchronization indicative of
slow-wave sleep (SWS) in an awake animal [14]. Conversely,
lesions of the dorsal reticular formation and of the NTS
produced desynchronization of the EEG in a sleeping animal
[15]. These results all suggest the existence of neurons in
the NTS that are involved in generating sleep. Furthermore,
microinjection of morphine into the NTS provokes an
enhancement of SWS and this eﬀect is blocked by nalox-
one [16], suggesting the somnogenic eﬀect of opioidergic
system in the NTS. Our previous observations demonstrate
that activation of cholinergic system in the caudal NTS
of the medulla oblongata mediates the enhancement of
non-rapid eye movement (NREM) sleep induced by EA
stimulation of Anmian (EX17) acupoints [17]. Nonetheless,
EA may also increase β-endorphin concentrations in the
NTS, which subsequently alter sleep, because the NTS area
is one of the anatomically distinct β-endorphin pathways
in the brain inﬂuenced by EA [18]. Therefore, this study
was designed to further clarify whether the activation of
cholinergic system in the NTS after EA stimuli enhances
endogenous opioidergic activity and what type(s) of opi-
oid receptors are involved in EA-induced alterations in
sleep.
2. Methods
2.1. Pharmacological Agents. Stock solutions of muscarinic
receptor antagonist, scopolamine hydrobromide (Sigma, St
Louis, MO, USA), a broad-spectrum opioid antagonist
(naloxone hydrochloride (Tocris, Bristol, UK)), a μ-receptor
antagonist (naloxonazine dihydrochloride (Tocris)), a δ-
receptor antagonist (naltrindole hydrochloride (Tocris)) and
a κ-receptor antagonist (nor-binaltorphimine dihydrochlo-
ride (Tocris)) were dissolved in pyrogen-free saline (PFS).
T h es t o c ks o l u t i o n sw e r es t o r e da t4 ◦C until use. The dose of
scopolamine used was 20μgμL−1, whereas naloxone, nalox-
onazine, naltrindole and nor-binaltorphimine were microin-
jected at three diﬀerent doses, 0.1, 1.0 and 10μgμL−1.
The total volume used for each microinjection was
1μL.
2.2. Animals. Male Sprague-Dawley rats (250–300g;
National Laboratory Animal Breeding and Research Center,
Taiwan) were used in this study. Rats were anesthetized by
intraperitoneal injection with ketamine/xylazine (87/
13mgkg−1) and were given an analgesic (1mg/rat
morphine) and an antibiotic (5000IU/rat penicillin G ben-
zathine) to reduce pain and avoid infection. Rats were
surgically implanted with three electroencephalogram
(EEG) screw electrodes as earlier described [19] and the
microinjection guide cannulae directed into the NTS (AP,
13.30mm from bregma; ML, 1.2mm and DV, 8.2mm
relative to bregma). The coordinates were adopted from
the Paxinos and Waton rat altas [20]. Two unilateral screw
EEG electrodes were placed over the right hemisphere of
the frontal and parietal cortices and a third EEG electrode
was placed over the cerebellum and served to ground the
animal to reduce signal artifacts. Insulated leads from
EEG electrodes were routed to a Teﬂon pedestal (Plastics
One, Roanoke, VA, USA). The Teﬂon pedestal was then
cemented to the skull with dental acrylic (Tempron, GC
Co., Tokyo, Japan). The incision was treated topically with
polysporin (polymixin B sulfate—bacitracin zinc) and the
a n i m a l sw e r ea l l o w e dt or e c o v e rf o r7d a y sp r i o rt ot h e
initiation of experiments. The rats were housed separately in
individual recording cages in the isolated room, in which the
temperature was maintained at 23 ± 1◦C and the light:dark
rhythm was controlled in a 12:12h cycle (40 Watt × 4t u b e s
illumination). Food (5001 rodent diet, LabDiet) and water
were available ad libitum. All procedures performed in this
study were approved by the National Taiwan University
Animal Care and Use Committee.
2.3. Experimental Protocol. On the second postsurgical day,
the rats were connected to the recording apparatus via a
ﬂexible tether. As such, the rats were allowed relatively
unrestrictedmovementwithintheirowncages.Threegroups
of rats were used in the study as follows: Group 1 (n = 8) was
used to determine the eﬀects of opioid receptor antagonist
(naloxone) and μ-receptor antagonist (naloxonazine) on EA-
induced alterations in sleep; Group 2 (n = 8) was used to
elucidate the eﬀects of δ-receptor antagonist (naltrindole)
and κ-receptor antagonist (nor-binaltorphimine) on EA-
induced alterations in sleep; Group 3 (n = 24) was used
to depict the action of NTS muscarinic receptors on EA-
induced β-endorphin expression (determined by enzyme-
linked immunosorbent assay (ELISA)) after microinjection
of scopolamine into the NTS. One week after rats had
adapted to the 12:12h light : dark cycle after surgery, a 23-
h undisturbed baseline recordings were obtained beginning
at dark onset on the ﬁrst recording day in rats in Groups 1
and 2. When EA was given (see later), all rats were lightly
anesthetized with one-third of the dose of ketamine/xylazine
used in the surgery, after which rat wake-up time is 20–
25min.A20-minperiodofEAstimulationwasadministered
before the onset of the dark period. The anesthetization was
given 25min prior to the dark period onset and lasted for
20min. The rationale for carrying out the experiment in the
darkness is that rats are active with a lowest level of sleepEvidence-Based Complementary and Alternative Medicine 3
during the dark period, and a manipulation, if it possesses
ability to increase sleep, would signiﬁcantly augment sleep
during the dark period. In contrast, it may not be easy to
enhance sleep during the light period when sleep activity is
at its highest circadian level. Since we expected to ﬁnd a sleep
enhancement after the EA stimuli at the Anmian (EX17), we
therefore manipulated the EA stimulation before the onset
of the dark period and analyzed the sleep alteration during
the subsequent dark period. The rats in group 1 were both
administered PFS intraperitoneally (IP) and microinjected
into the NTS (ipPFS + PFS) at 25min prior to the dark onset
on two consecutive days, and recordings obtained for 24-h
beginningafterthesecondinjection.Theeﬀectsofanesthesia
with the NTS microinjection of PFS (ipketamine + PFS) on
sleepweredeterminedafterIPinjectionofketamine/xylazine
and the NTS PFS microinjection on two consecutive days.
A sham EA (ipketamine + PFS + sham EA) was delivered
to control for the non-speciﬁc eﬀect of the electrical stim-
ulation, although our previous study had conﬁrmed that no
non-speciﬁc eﬀect was observed after the sham EA [17]. The
EA stimuli under anesthesia (ipketamine + PFS + EA) were
alsoperformedbeforethedarkonsetontwoconsecutivedays
and sleep-wake behavior after the second EA stimulation
was then determined. Subsequently, three diﬀerent doses
(0.1, 1.0 and 10μg) of naloxone (ipketamine + naloxone +
EA) and naloxonazine (ipketamine + naloxonazine + EA)
were administered 25min prior to the dark onset on the
second day of EA stimulation and the 24-h sleep pattern was
determined. At least 1 day without injections was scheduled
between each manipulation. The EA stimulus was delivered
via the bilateral insertion of stainless needles (32 gauge ×
1
  , Shanghai Yanglong Medical Articles Co.) on Anmian
(EX17) points in the depth of 2mm. The stimulus consisted
of a train of biphasic pulses (150μs duration each) of 10Hz
with intensity of 3mA, and was delivered by Functions
Electrical Stimulator (Trio 300, I.T.O., Japan). The acupoint
“Anmian(EX17)”islocatedatmidpointbetweenYifeng(TH
17) and Fengchi (GB 20); Yifeng (TH 17) locates posterior
to the lobule of the ear in the depression between the
mandible and mastoid process and Fengchi (GB 20) locates
in the depression between the upper portion of musculus
sternocleidomastoideus and musculus trapezius in human.
The location of Anmian (EX17) in rats is at the relative
anatomical location between the strenocleidomastoideus
muscle and the splenius capitis muscle, as in the human
acupoint map. Sham EA was performed by stimulation of a
non-acupoint located at the ventral conjunction between the
forelimb and the trunk as described earlier [17]. Those rats
in group 2 underwent a similar protocol to those in group
1, except that the substances administered were naltrindole
(ipketamine + naltrindole + EA) and nor-binaltorphimine
(ipketamine + nor-binaltorphimine + EA). Rats in group 3
were divided into four subgroups and received ipketamine +
PFS, ipketamine + PFS + sham EA, ipk e t a m i n e+P F S+E A
and ipketamine + scopolamine + EA, respectively. Microin-
jection of scopolamine into the NTS was administered prior
to the second EA stimulation. Rats were then decapitated
at the dark onset and ﬁve distinct brain regions, including
the hypothalamus, cortex, brainstem, hippocampus and
striatum, were dissected and frozen in −80◦C until assay.
These tissues were used for β-endorphin ELISA as described
in the following.
2.4. Apparatus and Recording. Signals from the EEG elec-
trodes were fed into an ampliﬁer (Colbourn Instruments,
Lehigh Valley, PA; model V75-01). The EEG was ampliﬁed
(factor of 5000) and analog bandpass ﬁltered between 0.1
and 40Hz (frequency response: ±3dB;ﬁlterfrequencyroll
oﬀ: 12dB/octave). Gross body movements were detected by
custom-made infrared-based motion detectors (Biobserve
GmbH, Germany) and the movement activity was converted
to a voltage output which was digitized and integrated into
1-s bins. These conditioned signals (EEGs and gross body
movements) were subjected to analog-to-digital conversion
with 16-bit precision at a sampling rate of 128Hz (NI PCI-
6033E; National Instruments, Austin, TX). The digitized
EEG waveform and integrated values for body movement
were stored as binary computer ﬁles pending subsequent
analyses.
Postacquisition determination of the vigilance state was
done by visual scoring of 12-s epochs using custom software
(ICELUS, M. R. Opp) written in LabView for Windows
(National Instruments). The animal’s behavior was classiﬁed
as SWS, rapid eye movement sleep (REMS) or waking
based on previously deﬁned criteria [19]. Brieﬂy, SWS is
characterized by large-amplitude EEG slow waves, high
power density values in the delta frequency band (0.5–
4Hz) and lack of gross body movements. During REMS,
the amplitude of the EEG is reduced, the predominant EEG
power density occurs within the theta frequency (6–90Hz)
and there are phasic body twitches. During waking, the rats
are generally active. There are protracted body movements.
The amplitude of the EEG is similar to that observed during
REMS, but power density values in the delta frequency band
are generally greater than those in theta frequency band. In
addition to the amount of time spent in each vigilance state,
the number and duration of individual bouts of behaviors
weredeterminedusingcriteriamodiﬁedfromthoseofTobler
and colleagues [21, 22], as described earlier [19].
2.5. ELISA for β-Endorphin. Rat β-endorphin ELISA
kits were obtained from Phoenix Pharmaceuticals Inc.
(Burlingame, CA, USA) and the procedures followed the
standard instructions provided by the manufacturers.
Absorbance was measured by an ELISA plate reader
(Multiskan EX, Thermo Electron Corp., Waltham, MA,
USA) with the wavelength set at 450 and 550nm. The
sensitivity is 0.21ngmL−1, the assay range is between 0.21
and 3.15ngmL−1, the intra-assay coeﬃcient of variation
is <5% and the inter-assay coeﬃcient of variation is
<14%. There is no cross-reactivity for met-enkephalin and
leu-enkephalin.
2.6. Statistical Analyses for Experiment Protocol. All values
acquired from sleep-wake recording were presented as the
mean ± SEM for the indicated sample sizes. One-way analy-
ses of variance (ANOVA) for the duration of each vigilance4 Evidence-Based Complementary and Alternative Medicine
state (SWS, REMS, WAKE) and for sleep architecture
parameters were performed, comparing before and after
manipulation within subjects, across a certain of time block.
An α level of P ≤ .05 was taken as indicating a statistically
signiﬁcant diﬀerence. If statistically signiﬁcant diﬀerences
were detected, a Scheﬀe post hoc comparison was made
to determine which hourly intervals during experimental
conditions deviated from values obtained from the same
animals during control conditions. The statistical evaluation
for the β-endorphin ELISA used an unpaired Student’s t-test
comparing the averages between the groups analyzed.
3. Results
3.1. Naloxone and Naloxonazine Blocked the EA-Induced
Alterations in Sleep. Anesthetization of rats for 25min
with ketamine/xylazine prior to the dark period suppressed
both NREM and REM sleep for the ﬁrst 4h of the dark
period. The time spent in NREM sleep during the ﬁrst 4-
h period after ipketamine + PFS decreased to 10.8 ± 2.5%
from 22.4 ± 2.5% acquired after ipPFS + PFS (F(1,62) =
10.711, P = .002, Figures 1(a) and 1(b)). REM sleep was
suppressed from 6.5 ± 1.8% obtained after ipP F S+P F S
to 0.8 ± 0.3% acquired after ipketamine + PFS (F(1,62) =
8.697, P = .005, Figures 1(c) and 1(d)). A concomitant
enhancement of wakefulness was observed during the ﬁrst
4hafterreceivingketamineanesthetization(Figures1(e)and
1(f)).ApplicationofshamEAdidnotalteranyaspectofsleep
parameters (data not shown), which is similar to our pre-
vious observation [17]. Twenty-minute EA stimuli delivered
before the dark period on two consecutive days signiﬁcantly
augmented NREM sleep during post-manipulation 5–8h.
The percentage of time spent in NREM sleep during 5–
8h increased from 18.3 ± 2.7% obtained after ipketamine
+ PFS to 34.0 ± 3.8% after vketamine + PFS + EA (F(1,62)
= 9.180, P = .004, Figures 1(a) and 1(b)). Analysis of
12-h dark period revealed that NREM sleep was enhanced
from 14.8 ± 1.5% after ipketamine + PFS to 21.7 ± 2.1%
after ipk e t a m i n e+P F S+E A( F(1,190) = 6.923, P = .010).
REM sleep was not signiﬁcantly altered by EA. A decrease
of waking at the expense of SWS was observed during 5–8h
(Figures 1(e) and 1(f)).
Administration of three diﬀerent doses (0.1, 1.0 and
10.0μg) of naloxone, a broad-spectrum opioid antagonist,
into the NTS dose-dependently blocked EA-induced
increases of NREM sleep, especially during post-
manipulation 5–8h (Figures 2(a) and 2(b)). Across the
entire 12-h dark period recording, NREM sleep was
suppressed from 21.7 ± 2.1% after ipketamine + PFS +
EA to 13.4 ± 2.1% after ipketamine + naloxone (10.0μg)
+E A( F(1,190) = 7.631, P = .007, Figures 2(a) and 2(b)).
Administration of μ-opioid receptor antagonist, naloxon-
azine, also exhibited a dose-dependent blockade of EA-
induced NREM sleep enhancement (Figures 2(a) and 2(b)).
Administration of 10μg naloxonazine reduced NREM
sleep from 21.7 ± 2.1% after ipk e t a m i n e+P F S+E At o
14.9 ± 2.1% (F(1,190) = 5.100, P = .026, Figures 2(a) and
2(b)) during the 12-h dark period. Neither naloxone nor
naloxonazine altered REM sleep (Figures 2(c) and 2(d)).
Am i r r o re ﬀect on the EA-induced decrease of waking was
also been observed for both naloxone and naloxonazine
(Figures 2(e) and 2(f)).
Analysis of sleep architecture parameters across 1–12h
during the dark period revealed that the eﬀect of ketamine
on the suppression of NREM and REM sleep was primarily
due to an increase in episode duration of waking, although
therewasatendencyfordecreasesinbothREMsleepepisode
number and in NREM sleep episode duration (Table 1).
The increase of NREM sleep after EA stimuli was primarily
because of the increase in the duration of a single episode
(Table 1), which is similar to our previous result [17]. Eﬀects
of naloxone and naloxonazine on blocking EA-induced
enhancement of NREM sleep were mediated by reversing the
EA-induced augmentation of NREM sleep episode duration
(Table 1).
3.2. Naltrindole and Nor-Binaltorphimine Did Not Aﬀect EA-
Induced Alterations in Sleep. Administration of either the
δ-opioid receptor antagonist naltrindole or the κ-receptor
antagonist nor-binaltorphimine prior to EA stimulation
did not aﬀect EA-induced alterations in sleep (Figure 3).
Similarly, these antagonists did not alter any aspect of sleep
architecture (data not shown).
3.3. Scopolamine Suppressed EA-Induced Expression of
Endogenous β-Endorphin. Our result demonstrated that
delivery of sham EA stimuli did not alter the concentrations
of β-endorphin within ﬁve distinct brain structures,
including the brainstem, hypothalamus, cortex, hippo-
campus and striatum (Figure 4). However, application of EA
stimuli at Anmian (EX17) acupoints for 20min signiﬁcantly
enhanced the levels of β-endorphin in the brainstem and
hippocampus, but not in the cortex, hypothalamus and
striatum (Figure 4). Administration of the muscarinic
receptor antagonist scopolamine directly into the NTS
before the EA stimuli blocked EA-induced increases of
β-endorphin in the brainstem and hippocampus (Figure 4).
4. Discussion
Insomnia is a common sleep complaint among elderly
people and young adults, which may result from psychiatric
illness, sociopsychological stress, a medical problem, poor
sleep habits or a primary sleep disorder. Epidemiological
surveys have shown that 10%–20% of adults have suﬀered
from moderate to severe insomnia [23], although the
percentage is lower than that of 40%–70% of healthy elderly
people who suﬀer from chronic sleep disturbances [24].
Sedative-hypnotic medications, including benzodiazepines
and non-benzodiazepines, are the most common treatments
for insomnia. However, there are concerns regarding the
inappropriate use, dependence and adverse eﬀects of these
agents. On the other hand, acupuncture has been used for
relieving sleep disturbances for thousands of years in China.
Although acupuncture is eﬃcacious for sleep problems,
especiallyforinsomnia,theunderlyingmechanismswherebyEvidence-Based Complementary and Alternative Medicine 5
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Figure 1: The eﬀects of low-frequency (10Hz) stimulation by EA at Anmian (EX17) acupoints on vigilance states. The 10Hz EA enhanced
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Table 1: Eﬀects of naloxone and naloxonazine on the alterations of sleep-wake architecture parameters induced by EAc of Anmain (EX17)
acupoints in rats.
Manipulationd Hour
L:D
cyclee
Number of boutsa Bout durationb
Transitionsc
WAKEf NREMSf REMSf WAKE NREMS REMS
ipPFS + PFS 1–12 D 3.98 ± 0.31 5.06 ± 0.45 1.58 ± 0.26 18.54 ± 2.20 1.67 ± 0.15 0.67 ± 0.10 26.94 ± 2.31
ipKetamine + PFS 1–12 D 3.52 ± 0.36 4.40 ± 0.46 1.20 ± 0.24 24.12 ± 2.97∗ 1.44 ± 0.15 0.59 ± 0.10 25.93 ± 2.62
ipKetamine + PFS +
EAc
1–12 D 3.43 ± 0.30 4.75 ± 0.46 1.38 ± 0.24 20.57 ± 2.65 2.13 ± 0.20# 0.54 ± 0.09 28.81 ± 2.60
ipKetamine +
naloxone + EAc
1–12 D 3.20 ± 0.44 3.48 ± 0.58 1.21 ± 0.26 29.17 ± 3.53$ 1.15 ± 0.20$ 0.66 ± 0.11 28.22 ± 3.51
ipKetamine +
naloxonazine + EAc
1–12 D 3.19 ± 0.43 4.27 ± 0.65 0.98 ± 0.21$ 26.16 ± 3.30 1.26 ± 0.17$ 0.48 ± 0.10 27.93 ± 3.53
Values are means ± SEM.
a Numberofboutsperhour(mean ± SEM)foreachvigilancestate; bMean (±SEM)boutduration(min)foreachvigilancestate; cNumberoftransitionsfrom
one behavioral state to another (mean ± SEM) per hour; dExperimental manipulation; ePeriod of the light:dark cycle immediately prior to which injections
were given: D = dark period; fVigilance states: WAKE, wakefulness; NREMS, non-rapid eye movement sleep; REMS, rapid eye movements sleep; ∗Denotes
a statistically signiﬁcant diﬀerence (P<. 05) between values obtained after administration of ipPFS + PFS and those obtained after receiving ipketamine +
PFS; #Depicts a statistically signiﬁcant diﬀerence (P<. 05) between values obtained after ipketamine + PFS + EAc and those obtained after ipketamine + PFS;
$Depicts a statistically signiﬁcant diﬀerence (P<. 05) after either receiving naloxone or naloxonazine.
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Figure 4: The eﬀects of scopolamine on the 10Hz EA stimuli-
inducedincreaseofβ-endorphin.The10HzEAstimulisigniﬁcantly
increased the expressions of β-endorphin in the brainstem and
hippocampus and administration of scopolamine blocked EA-
induced increases of β-endorphin concentration. ∗Represents a
statistically signiﬁcant diﬀerence between the values obtained from
ipketamine+PFS+EAand ipketamine+PFS+shamEA. #Depictsa
statistically signiﬁcant diﬀerence between the values obtained from
ipketamine + scopolamine + EA and ipk e t a m i n e+P F S+E A .
sleep is improved by acupuncture are poorly understood.
We, therefore, designed this study to determine whether the
opioidergic system of the NTS plays a role in EA-induced
alterations in sleep. Our current results demonstrate that EA
stimuli of Anmian (EX17) acupoints in anesthetized rats for
20min enhances NREM sleep during the subsequent dark
(active) period. This observation is a further conﬁrmation
of the ability of EA stimuli at Anmian (EX17) acupoints to
increaseNREMsleep.InordertoperformtheEAstimulation
easily, rats were lightly anesthetized. We found that both
NREM and REM sleep during the ﬁrst 4h of the dark
period were decreased after rats recovered from the ketamine
anesthetic. Ketamine, a cyclohexanone derivative, is used
clinically as a dissociative anesthetic agent both in humans
and animals. Ketamine is a non-competitive N-methyl-D-
aspartate (NMDA) receptor antagonist that blocks cation
channels [25]. It has been demonstrated that administration
ofketamineorMK-801,anotherNMDAreceptorantagonist,
at sub-anesthetic doses produce a robust, dose-dependent
increase in the intensity of δ-power of the NREM sleep
[26, 27]. Furthermore, the eﬀect of MK-801 by increasing
the metabolic rate in the hippocampus and other limbic
structures stimulates physiological sleep that is similar to
the sleep that follows sleep deprivation, indicating the need
of homeostatic recovery [28]. Therefore, the suppression of
NREM and REM sleep after recovery from the ketamine
anesthetization during the beginning of the dark period may
be due to a homeostatic compensation to the previous anes-
thetic state. However, this explanation needs to be further
investigated. On the other hand, EA of other acupoints may
exhibitanoppositeeﬀectonsleeporanesthesia.Forexample,
EA stimulation of bilateral Neiguan (PC6) shortened the
post-anesthesia recovery time in cats [29]. However, EA of
Anmian (EX17) did not exhibit this eﬀect in our experiment.
We previously demonstrated that microinjections of
muscarinic receptor antagonist scopolamine into the NTS
and bilateral lesions of the caudal NTS blocks the alterations
in sleep induced by EA stimulation of Anmian acupoints
[17], implicating the involvement of cholinergic neurons
in the caudal NTS in this response. Nevertheless, endoge-
nous opiates (β-endorphin, enkepalin, endomorphin and
dynorphin) are well known to mediate the analgesic eﬀect
of EA; low frequency EA stimulation activates μ-a n dδ-
opioid receptors by the releases of β-endorphin, enkepalinEvidence-Based Complementary and Alternative Medicine 9
Vagus n. Ach Muscarinic
receptor β-endorphin μ-receptor
NREM
NTS
Figure 5: A hypothetical model by which EA Anmian (EX17) may alter NREM sleep. EA stimuli in the ﬁgure represents the electrical sign;
Ach: acetylcholine; electrical sign: EA stimuli.
and endomorphin, whereas high-frequency EA stimulation
activates the κ-receptors by enhancing the concentrations of
dynorphin [30, 31]. It has also been demonstrated that EA
increases β-endorphin concentrations in the arcuate nucleus
of the hypothalamus via Aβ and Aδ ﬁbers, which in turn
mediate the analgesic eﬀects of EA [32].
There are two anatomically distinct β-endorphin path-
ways in the brain; the major pathway originates in the
arcuate nucleus and the minor one is in the area of the
NTS of the caudal medulla [18]. Therefore, it is possibility
that β-endorphin concentrations may increase in the caudal
NTS after the EA stimulation. Reinoso-Barbero and de
Andres have shown that microinjection of morphine into
the NTS provokes a dose-dependent enhancement of the
polygraphic and behavioral manifestations of SWS. This
eﬀectisblockedbynaloxone,suggestingthattheendogenous
opioid is involved in controlling electrocortical activity
generated by the NTS [16]. Furthermore, it has been
documented that vagal aﬀerents activate the β-endorphin
system in the NTS, which in turn mediates responses to
vagal activation; the eﬀects of acetylcholine on depressive
responses in pulmonary and carotid arteries are mediated
by activating the serotonergic and endorphin system of the
NTS [33] and the inhibitory eﬀect of vagal aﬀerents on the
bradycardia response is mediated by β-endorphinergic neu-
rons in the NTS [9]. On the basis of our previous results [17]
and aforementioned evidence, we herein tried to elucidate
whether the eﬀects of EA on sleep regulation is mediated
by the increase of endogenous opiates and the activation
of opioidergic receptors in the caudal NTS via muscarinic
receptors. Application of naloxone, a broad spectrum of
opioid receptor antagonist, was used to determine the
involvement of NTS opioidergic receptors in the EA-induced
increase of NREM sleep. We found that administration of
naloxone directly into the caudal NTS dose-dependently
blocked EA-induced NREM sleep enhancement during the
dark period, but had no eﬀect on the REM sleep, implicating
the involvement of endogenous opiates in the NTS. A
potential role for three major opioid receptors, μ-, δ-a n d
κ-receptors, was then determined by application of speciﬁc
receptor antagonists. Our results demonstrate that naloxon-
azine, a μ-opioid receptor antagonist, exhibits a similar dose-
dependent eﬀect as that of naloxone, whereas naltrindole (a
δ-opioid receptor antagonist) and nor-binaltorphimine (a
κ-opioid receptor antagonist) have no eﬀect. These results
are in part consistent with the results reported by Reinoso-
Barbero and de Andres that administration of μ-and δ-
opioid receptor agonists, but not κ-opioid receptor agonist,
into the NTS in cats enhances NREM sleep and that REM
sleep is unchanged after NTS administration of the diﬀerent
opioids [16]. Nevertheless, our results implicate NTS μ-
opioid receptors as mediators of EA-induced NREM sleep
enhancement, which is similar to the eﬀect of μ-opioid
receptors on analgesia induced by low-frequency EA stimuli.
The frequency of EA we used in this study was 10Hz, which
is considered a low-frequency stimulation. Our results also
indicatethatconcentrationsofβ-endorphininthebrainstem
and hippocampus increase after EA stimuli, suggesting the
involvement of NTS β-endorphin. The enhancement of β-
endorphin in the hippocampus may be due to actions of
multisynaptic relays from the NTS to the hippocampus
[34]. Enkephalin- and β-endorphin-containing neurons are
in the NTS [35]. Therefore, the expression of enkephalin
and endorphin after low-frequency EA stimuli and the
expressionofdynorphinafterhigh-frequencyEAwouldbeof
interest for further investigation. Nevertheless, EA-enhanced
β-endorphin in the NTS is blocked by microinjection of
muscarinic receptor antagonist scopolamine, suggesting that
the activation of endogenous opioidergic system is mediated
by the NTS cholinergic nervous system.
In summary, our current results demonstrate that EA
stimuli of Anmian (EX17) acupoints enhance NREM sleep
and this enhancement is blocked by naloxone and nalox-
onazine, implicating μ-opioid receptors. Furthermore, the
activation of NTS muscrainic receptors after low-frequency
EA stimuli increases concentrations of β-endorphin, which
mediates the enhancement of NREM sleep after EA stimuli
of Anmian (EX17) acupoints. A diagram elucidating one10 Evidence-Based Complementary and Alternative Medicine
hypothetical mechanism by which EA of Anmian (EX17)
alters sleep is depicted in Figure 5.
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